Pharma Update

Tiragolumab in 1L NSCLC and 1L HCC SKYSCRAPER-01 continues to final OS analysis; Ph III in HCC initiated Ph III (SKY-01) trial design in 1L PDL1+ NSCLC Ph I/II (MORPHEUS) results in 1L HCC • • Roche 2023 ASCO ANNUAL MEETING Tiragolumab 1200mg IV Q3W Atezolizumab 600mg IV Q3W PD or ORR PFS* 43% 100 HR 0.42 Screening (n=660) R loss of (95% CI: 27.0, 59.1) 95% CI: 0.22, 0.82 1:1 clinical Placebo IV Q3W Atezolizumab 600mg IV Q3W benefit 11% (95% CI: 1.4, 34.7) Probability of PFS (%) 75 50 At the 1st interim primary PFS endpoint not met; however, a numeric improvement was observed in both PFS and OS and curves were separating Inadvertent disclosure of 2nd interim analysis of SKYSCRAPER-01: study is ongoing and remains blinded to patients and investigators We are continuing the study as planned until the final analysis for overall survival . At the 2nd interim OS was immature with a mOS of 22.9m for tiragolumab - Tecentriq vs 16.7m for Tecentriq (HR=0.81); no new safety signals + • 25 +IMbrave 150: atezo+bev (n-336) + MORPHEUS: atezo + bev (n=18) 0 atezo + bev tira + atezo + MORPHEUS: tira + atezo+ bev (n=40) 0 2 4 6 8 + bev 10 12 14 Time (months) 16 18 20 22 24 26 Tiragolumab + Tecentriq + Avastin with an ORR of 43% and a PFS benefit of 58% (HR=0.42) . . Treatment benefit supported by benchmarking vs Ph III IMbrave 150 data No new safety signals Finn R, et al. ASCO 2023; NSCLC=non-small cell lung cancer; HCC-hepatocellular carcinoma; PFS-Progression-free survival; OS-Overall survival; mOS-median overall survival; m=month; Cl=confidence interval; ORR=overall response rate; HR-hazard ratio; PD=progressive disease; IV-intravenous; Q3W-every 3 weeks 73

View entire presentation